Leading the Way in Life Science Technologies

GEN Exclusives

More »
GEN Podcasts Back to Item »

FACING BIOTECH'S CHALLENGES AND SEIZING OPPORTUNITIES IN 2009

- Interview with Joshua Boger, Ph.D., Founder and CEO, Vertex Pharmaceuticals, and Chairman, Board of Directors, Biotechnology Industry Organization (BIO), and James Greenwood, President and CEO, BIO



  • Click here to Login or to Register for free.

    You will be taken back to your selected item after Login/Registration.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »